IPP Bureau
50% of the world's population expected to be myopic by 2050
By IPP Bureau - May 23, 2022
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Dapagliflozin met primary endpoint in DELIVER Phase III trial
By IPP Bureau - May 23, 2022
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
New study finds that Masimo PVi may be useful in helping ER doctors determine the severity of asthma attacks
By IPP Bureau - May 23, 2022
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland
By IPP Bureau - May 23, 2022
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Soligenix receives US patent allowance for its thermostabilized vaccine platform
By IPP Bureau - May 23, 2022
Includes thermostabilized Ebola vaccines
Micro-Tech Endoscopy partners with Wision A.I. to distribute polyp detection software in the U.S.
By IPP Bureau - May 23, 2022
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
Glenmark Pharma gets observations from USFDA for its Goa and Monroe facilities
By IPP Bureau - May 22, 2022
A total of five observations for Goa and 17 for Monroe
Karkinos Healthcare receives investment from Mayo Clinic
By IPP Bureau - May 22, 2022
Investment with representation on the Board of Directors and technical know-how
Govt. launches single national portal for biotech researchers and start-ups
By IPP Bureau - May 22, 2022
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Novavax files for expanded conditional marketing authorisation for Nuvaxovid as a booster in Europe
By IPP Bureau - May 21, 2022
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
USFDA approves Dupixent as first treatment for 12 and older with eosinophilic esophagitis
By IPP Bureau - May 21, 2022
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
Novartis Cosentyx receives positive CHMP opinion for use in childhood arthritic conditions
By IPP Bureau - May 21, 2022
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
AbbVie submits NDA for treatment of advanced Parkinson’s disease
By IPP Bureau - May 21, 2022
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Aarogya Pay to make healthcare accessible for patients
By IPP Bureau - May 21, 2022
As part of Aarogya Pay, QR codes will be installed at doctors’ clinics that patients can scan to avail instant medical loans at 0% interest and 3/6 EMIs.
Medical students to learn key medical skills and other patient diagnosis in VR
By IPP Bureau - May 21, 2022
The new lab is a testament to the Pondicherry Institute of Medical Sciences (PIMS)’s long-held values and traditions of striving for excellence and embracing newer innovations in order to deliver the best standard of training for their students
